SSRI ‘discontinuation syndrome’ or withdrawal

This Analysis by Massabki and Abi-Jaoude has been published in the British Journal of Psychiatry. It has been made open-access.

Protected: A published and an unpublished review of ‘Bad Pharma’

There is no excerpt because this is a protected post.

Esketamine: Regulators and a confusing narrative

I recently shared a BMJ report that outlined the approval of Esketamine in Europe: Since sharing this news, the following rapid response by the MHRA [The Medicines and Healthcare products … Continue reading Esketamine: Regulators and a confusing narrative

“The influence of pharma on most psychiatrists in the UK is negligible”

Professor Wendy Burn, President of the Royal College of Psychiatrists [24 December 2019]: “The influence of pharma on most psychiatrists in the UK is negligible.” As we say in Scotland: … Continue reading “The influence of pharma on most psychiatrists in the UK is negligible”